Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024PR Newswire • 16 days ago
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 Nuvalent Presents New...
Share to Feed
Related Stocks: NUVL...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) insider Deborah Ann Miller sold 22,000 shares of the business's stock in a transaction dated Thursday, March 28th. The stock was sold at an average...
Related Stocks: NUVL...
Nuvalent, Inc. (NASDAQ:NUVL Get Free Report) has been given a consensus recommendation of Moderate Buy by the nine brokerages that are covering the firm, MarketBeat.com reports...
Ellsworth Advisors LLC trimmed its position in shares of Nuvalent, Inc. (NASDAQ:NUVL Free Report) by 4.4% during the 4th quarter, according to its most recent Form 13F filing with the...
Nuvalent, Inc. (NASDAQ:NUVL Get Free Report) insider Darlene Noci sold 20,000 shares of the stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $77.51...
Related Stocks: NUVL...